Open AccessEffectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
Author(s) -
Mousumee Panigrahi,
Trupti Rekha Swain,
Rabindra Kumar Jena,
Ashutosh Panigrahi,
Nishant Debta
Publication year - 2020
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/ijp.ijp_68_18
Subject(s) - deferasirox , medicine , thalassemia , chelation therapy , deferiprone , pediatrics , beta thalassemia , prospective cohort study , ferritin , deferoxamine , surgery , gastroenterology
Patients with beta-thalassemia require lifelong blood transfusions, leading to chronic iron overload, which can lead to growth retardation, as well as hinder sexual development during the adolescent period and dysfunction of organs such as heart, pancreas, and endocrine glands. These patients are in need of lifelong transfusion therapy and hence lifelong iron chelation therapy as well. Hence, this study was aimed to assess the effectiveness of deferasirox for iron chelation in pediatric thalassemia cases in a tertiary care hospital of Eastern India.